Mark Guinan - Myovant Sciences Independent Director
| MYOVDelisted Stock | USD 26.98 0.01 0.04% |
Director
Mr. Mark J. Guinan is Director of the Company since 2018.
| Age | 59 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Phone | 44 20 7400 3351 |
| Web | https://myovant.com |
Myovant Sciences Management Efficiency
The company has return on total asset (ROA) of (0.1822) % which means that it has lost $0.1822 on every $100 spent on assets. This is way below average. Myovant Sciences' management efficiency ratios could be used to measure how well Myovant Sciences manages its routine affairs as well as how well it operates its assets and liabilities.Myovant Sciences currently holds 358.7 M in liabilities with Debt to Equity (D/E) ratio of 138.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Myovant Sciences has a current ratio of 1.79, which is within standard range for the sector. Note, when we think about Myovant Sciences' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 13 records | DIRECTOR Age | ||
| Sergio Rial | Delta Air Lines | 60 | |
| William Easter | Delta Air Lines | 71 | |
| Ashton Carter | Delta Air Lines | 66 | |
| Sherry Wilson | Allegiant Travel | N/A | |
| David DeWalt | Delta Air Lines | 56 | |
| Michael Huerta | Delta Air Lines | 63 | |
| David Taylor | Delta Air Lines | 62 | |
| Jeanne Jackson | Delta Air Lines | 68 | |
| CHRISTOPHER HAZLETON | Delta Air Lines | 52 | |
| Koosh Patel | JetBlue Airways Corp | N/A | |
| Kathy Waller | Delta Air Lines | 61 | |
| George Mattson | Delta Air Lines | 54 | |
| Dan Dorenkamp | National CineMedia | N/A | |
Management Performance
| Return On Asset | -0.18 |
Myovant Sciences Leadership Team
Elected by the shareholders, the Myovant Sciences' board of directors comprises two types of representatives: Myovant Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Myovant. The board's role is to monitor Myovant Sciences' management team and ensure that shareholders' interests are well served. Myovant Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Myovant Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frank Karbe, Principal Financial and Accounting Officer, President and Chief Financial Officer of Myovant Sciences, Inc. | ||
| Juan Ferreira, Chief Commercial Officer - Myovant Sciences, Inc | ||
| Ann Tomlin, VP HR | ||
| Juan MD, Chief Officer | ||
| Uneek Mehra, Chief Financial and Business Officer, Principal Financial and Accounting Officer | ||
| Nancy Valente, Director | ||
| Andria MD, Head Pharmacovigilance | ||
| Matthew JD, Gen Sec | ||
| Jeffrey Nornhold, Senior Vice President Pharmaceutical Operations & Development | ||
| Albert Liao, Director Communications | ||
| Matthew Lang, General Counsel, Corporate Secretary and Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences, Inc. | ||
| Kathleen Sebelius, Lead Independent Director | ||
| Adele Gulfo, Director, Interim Chief Commercial Officer | ||
| Mark Guinan, Independent Director | ||
| Myrtle Potter, Chairman of the Board | ||
| David Marek, Principal Executive Officer, Director | ||
| Terrie Curran, Independent Director | ||
| Hiroshi Nomura, Director | ||
| Bryan Selby, VP Devel | ||
| Lauren Merendino, Chief Commercial Officer |
Myovant Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Myovant Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.18 | |||
| Profit Margin | (0.48) % | |||
| Operating Margin | (0.39) % | |||
| Current Valuation | 2.6 B | |||
| Shares Outstanding | 97.26 M | |||
| Shares Owned By Insiders | 48.61 % | |||
| Shares Owned By Institutions | 56.21 % | |||
| Number Of Shares Shorted | 8.39 M | |||
| Price To Earning | (8.56) X | |||
| Price To Book | 70.01 X |
Thematic Opportunities
Explore Investment Opportunities
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in Myovant Stock
If you are still planning to invest in Myovant Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Myovant Sciences' history and understand the potential risks before investing.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |